341 related articles for article (PubMed ID: 21328441)
1. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
Candrilli SD; O'Brien SH; Ware RE; Nahata MC; Seiber EE; Balkrishnan R
Am J Hematol; 2011 Mar; 86(3):273-7. PubMed ID: 21328441
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.
Stallworth JR; Jerrell JM; Tripathi A
Am J Hematol; 2010 Oct; 85(10):795-7. PubMed ID: 20645429
[TBL] [Abstract][Full Text] [Related]
3. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
Kang HA; Barner JC
J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
[No Abstract] [Full Text] [Related]
4. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
[TBL] [Abstract][Full Text] [Related]
6. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
Blinder MA; Vekeman F; Sasane M; Trahey A; Paley C; Duh MS
Pediatr Blood Cancer; 2013 May; 60(5):828-35. PubMed ID: 23335275
[TBL] [Abstract][Full Text] [Related]
7. Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.
Kang HA; Barner JC; Lawson KA; Rascati K; Mignacca RC
Am J Hematol; 2023 Jan; 98(1):90-101. PubMed ID: 36251408
[TBL] [Abstract][Full Text] [Related]
8. Examining the effectiveness of hydroxyurea in people with sickle cell disease.
Lanzkron S; Haywood C; Fagan PJ; Rand CS
J Health Care Poor Underserved; 2010 Feb; 21(1):277-86. PubMed ID: 20173269
[TBL] [Abstract][Full Text] [Related]
9. Medical utilization and costs associated with statin adherence in Medicaid enrollees with type 2 diabetes.
Wu J; Seiber E; Lacombe VA; Nahata MC; Balkrishnan R
Ann Pharmacother; 2011 Mar; 45(3):342-9. PubMed ID: 21325098
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of adenotonsillectomy in reducing obstructive sleep apnea, cerebrovascular ischemia, vaso-occlusive pain, and ACS episodes in pediatric sickle cell disease.
Tripathi A; Jerrell JM; Stallworth JR
Ann Hematol; 2011 Feb; 90(2):145-50. PubMed ID: 20714723
[TBL] [Abstract][Full Text] [Related]
11. The cost of health care for children and adults with sickle cell disease.
Kauf TL; Coates TD; Huazhi L; Mody-Patel N; Hartzema AG
Am J Hematol; 2009 Jun; 84(6):323-7. PubMed ID: 19358302
[TBL] [Abstract][Full Text] [Related]
12. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
Armstrong EP; Skrepnek GH; Sasane M; Snodgrass SM; Ballas SK
J Med Econ; 2013; 16(1):10-8. PubMed ID: 22947171
[TBL] [Abstract][Full Text] [Related]
13. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
[TBL] [Abstract][Full Text] [Related]
14. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes.
de Montalembert M; Brousse V; Elie C; Bernaudin F; Shi J; Landais P;
Haematologica; 2006 Jan; 91(1):125-8. PubMed ID: 16434381
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
Davis KL; Candrilli SD; Edin HM
Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
[TBL] [Abstract][Full Text] [Related]
16. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
Vekeman F; Sasane M; Cheng WY; Ramanakumar AV; Fortier J; Qiu Y; Duh MS; Paley C; Adams-Graves P
J Med Econ; 2016; 19(3):292-303. PubMed ID: 26618853
[TBL] [Abstract][Full Text] [Related]
17. [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].
Mellouli F; Bejaoui M
Arch Pediatr; 2008 Jan; 15(1):24-8. PubMed ID: 18164913
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data.
Davis KL; Edin HM; Allen JK
Mov Disord; 2010 Mar; 25(4):474-80. PubMed ID: 20131374
[TBL] [Abstract][Full Text] [Related]
19. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
20. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
Tripathi A; Jerrell JM; Stallworth JR
Pediatr Blood Cancer; 2011 Jan; 56(1):90-4. PubMed ID: 20922765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]